Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS Author FAQs
    • COVID-19 submission information
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS Author FAQs
    • COVID-19 submission information
  • Alerts
  • Subscriptions

Population-based survey of antimycobacterial drug use among patients with non-tuberculosis mycobacterial pulmonary disease

Kiyohiko Izumi, Kozo Morimoto, Kazuhiro Uchimura, Manabu Ato, Naoki Hasegawa, Satoshi Mitarai
ERJ Open Research 2020 6: 00097-2019; DOI: 10.1183/23120541.00097-2019
Kiyohiko Izumi
1The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan
6These authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kizumi95@gmail.com
Kozo Morimoto
1The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan
2Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
6These authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuhiro Uchimura
1The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manabu Ato
3Leprosy Research Center, National Institute of Infectious Diseases, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Manabu Ato
Naoki Hasegawa
4Keio University School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoshi Mitarai
1The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan
5Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

This report shows poor adherence to the recommended treatment regimen for NTM-PD patients, which may pose a potential risk for the development of macrolide resistance. The risk was highest among elderly patients, and those with rheumatoid arthritis and COPD. http://bit.ly/3aBoUzE

To the Editor:

Macrolides are key drugs used to treat Mycobacterium avium complex (MAC) pulmonary disease (PD) [1, 2]. Members of this complex are the most frequently isolated mycobacterial species in many countries, including Japan [3], where 93.3% of nontuberculosis mycobacterial (NTM)-PDs are due to MAC [4]. The emergence of macrolide-resistant MAC, which has likely been induced by inappropriate treatment, (e.g. macrolide-containing regimens without appropriate companion medications and macrolide monotherapy), constitutes a serious challenge to MAC-PD patients, such as prolonged treatment duration and high mortality rate [5, 6]. However, little is known about the treatment practices of MAC-PD patients, especially inappropriate nonstandard treatment. Thus, we conducted a population-based cross-sectional study to describe antibiotic use among NTM-PD patients in Japan.

We used the Japanese national database (NDB), which collects nationwide data for all medical claims from public and private hospitals, pharmacies, and clinics in Japan, and electronically records all medical practices involving payment, such as diagnosis and the prescription of medications. We extracted from the NDB the claims of all individuals with ICD10 codes associated with NTM-PD (A310 and A319) in both in and outpatient claims between September 2009 and December 2014. Then, we defined and identified the incident NTM-PD patients as aged ≥40 years in 2011 who: 1) had not been issued any claims from September 2009 to December 2010; 2) had been issued at least five claims for NTM-PD between January 2011 and December 2014, with at least one issued in 2011; and 3) had been issued the claims for ≥24 months. Because most NTM-PD patients in Japan have MAC-PD, as mentioned above, and since claim data do not contain strain information, we used NTM-PD as a proxy for MAC-PD.

To evaluate antibiotics use, patients were classified as one of the following: “standard treatment” patients, who had received 1) macrolide and rifamycin and ethambutol, or 2) macrolide and ethambutol; “nonstandard treatment” patients, who had received the following regimens that diverge from guideline recommendations, 1) only macrolides, 2) macrolides and rifamycin, or 3) macrolides and fluoroquinolone; and “nontreatment” patients, who had not received any of the above treatments. Nonstandard treatment was basically defined as inappropriate treatment without ethambutol based on the findings of previous studies [5, 6]. Antibiotic use of any duration was included. We summarised patients' characteristics in each treatment category with respect to sex, age and comorbidities. We performed univariate and multivariate logistic regression to determine the factors associated with nonstandard treatment using standard treatment as the baseline. The model results are presented as unadjusted and adjusted odds ratios with 95% confidence intervals. The study protocol was approved by the Institutional Review Board of the Research Institute of Tuberculosis, Tokyo (RIT/IRB25-17) and Fukujuji Hospital, Tokyo (Fukujuji/IRB14005).

We identified 22 664 incident NTM-PD patients who met the aformentioned criteria. Of these patients, 6971 (30.8%) had received standard treatment; 8460 (37.3%) had received nonstandard treatment, representing 54.8% of all treated patients; and 7233 (31.9%) had not received treatment. More female patients received treatment (n=16 201; standard treatment 31.7%, nonstandard treatment 37.7%, nontreatment 30.7%) than male patients (n=6463; standard treatment 28.4%, nonstandard treatment 36.5%, nontreatment 35.1%).

The proportion of patients treated with nonstandard treatment continuously increased with increasing age (26.5% at 40–49 years, 32.0% at 50–59 years, 33.6% at 60–69 years, 38.7% at 70–79 years and 44.9% at ≥80 years) while the proportion of patients treated with standard treatment decreased over the same age groups (39.5%, 38.5%, 34.6%, 29.4% and 21.9% respectively). The proportion of patients who did not receive treatment remained relatively stable with age in all age groups (34.0%, 29.6%, 31.7%, 31.9% and 33.2%).

In the univariate analyses, the factors that were significantly associated with nonstandard treatment included male sex, age ≥50 years (when compared with age 40–49 years), and having rheumatoid arthritis (RA), chronic obstructive pulmonary disease (COPD), sequelae of pulmonary tuberculosis and interstitial pneumonia (table 1). After adjustment, the factors age ≥50 years, and having RA and COPD remained significantly associated with nonstandard treatment.

View this table:
  • View inline
  • View popup
TABLE 1

The demographic and clinical factors associated with nonstandard treatment

One-third of the patients with incident NTM-PD were observed to be undertreated with antimycobacterial drugs. This may reflect the predominance of nodular/bronchiectatic disease among NTM-PD patients in Japan, which may drive the high proportion of mild diseases and, therefore, the low percentage of patients receiving treatment [7]. Although all three drugs used in standard treatment have been covered by Japanese health insurance since 2009, many patients had been treated with nonstandard treatment. Such treatment may pose a potential risk for the development of macrolide resistance [5, 6]. This poor adherence to the recommended regimen was similar to the findings in the USA [8]. We showed the risk of nonstandard treatment was particularly prominent among elderly patients who could not probably comply with the standard treatment due to side-effects. RA and COPD were significant risk factors for receiving nonstandard treatment, implying that those patients may be intolerant to a three-drug regimen.

Some limitations may have biased the results of this study. Because the American Thoracic Society/Infectious Diseases Society of America diagnostic criteria could not be met due to the unavailability of bacteriological and clinical information, we may have overestimated the number of patients. However, it is also possible that we slightly underestimated the true number of patients, since we defined a case when at least five claims were made, the resulting estimates seem conservative relative to those of previous studies [9–11]. A short course of macrolide monotherapy may also have been provided to treat the common cold among untreated NTM-PD patients, which may have increased the proportion of nonstandard treatment use identified in our study because a minimum duration of treatment could not be considered for the treatment definition due to data analytic limitations. However, the risk of macrolide resistance associated with a very short course of macrolide monotherapy in patients with MAC-PD is unknown.

This is the first study to describe the current status of antibiotic use among NTM-PD patients in Japan and to examine the risk factors for receiving nonstandard treatment using the data covering the entire Japanese population. We identified a significant number of patients who received inappropriate treatments, which could potentially induce macrolide resistance. Macrolide-resistant NTM-PD can increase the patient care needed and healthcare-related costs [9]. Although the use of modified regimens, particularly for elderly patients, is unavoidable, inappropriate treatment should be minimised by enhancing the awareness of guideline-recommended treatment and promoting adherence to treatment, especially elderly patients with comorbidities. More detail on treatments including the duration of therapies and transitions between regimens require study to better understand the magnitude of gaps in practice patterns.

Acknowledgments

We would like to thank BIO Communications Inc. for preparing the dataset.

Footnotes

  • Conflict of interest: K. Izumi reports grants from the Japan Agency for Medical Research and Development, and the Ministry of Health, Labour and Welfare, during the conduct of the study.

  • Conflict of interest: K. Morimoto reports grants from the Japan Agency for Medical Research and Development during the conduct of the study; and was a coordinator of a clinical trial for Insmed outside the submitted work.

  • Conflict of interest: K. Uchimura reports grants from the Ministry of Health, Labour and Welfare, during the conduct of the study.

  • Conflict of interest: M. Ato reports grants from the Japan Agency for Medical Research and Development during the conduct of the study.

  • Conflict of interest: N. Hasegawa reports grants from the Japan Agency for Medical Research and Development during the conduct of the study; and was the coordinator of a clinical trial for Insmed, and received grants from Taisho-Toyama Pharmaceutical Co. Ltd and Nikon Co. Ltd, outside the submitted work.

  • Conflict of interest: S. Mitarai reports grants from the Japan Agency for Medical Research and Development, and the Ministry of Health, Labour and Welfare, during the conduct of the study.

  • Support statement: This research was supported by the Japan Agency for Medical Research and Development (AMED) (grant number: JP18fk0108043). Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received April 15, 2019.
  • Accepted January 12, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Griffith DE,
    2. Aksamit T,
    3. Brown-Elliott BA, et al.
    An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367–416. doi:10.1164/rccm.200604-571ST
    OpenUrlCrossRefPubMed
  2. ↵
    1. van Ingen J,
    2. Kuijper EJ
    . Drug susceptibility testing of nontuberculous mycobacteria. Future Microbiol 2014; 9: 1095–1110. doi:10.2217/fmb.14.60
    OpenUrlCrossRef
  3. ↵
    1. Hoefsloot W,
    2. van Ingen J,
    3. Andrejak C, et al.
    The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples. Eur Respir J 2013; 42: 1604–1613. doi:10.1183/09031936.00149212
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Morimoto K,
    2. Hasegawa N,
    3. Izumi K, et al.
    A Laboratory-based analysis of nontuberculous mycobacterial lung disease in Japan from 2012 to 2013. Ann Am Thorac Soc 2017; 14: 49–56. doi:10.1513/AnnalsATS.201607-573OC
    OpenUrlCrossRef
  5. ↵
    1. Griffith DE,
    2. Brown-Elliott BA,
    3. Langsjoen B, et al.
    Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006; 174: 928–934. doi:10.1164/rccm.200603-450OC
    OpenUrlCrossRefPubMed
  6. ↵
    1. Morimoto K,
    2. Namkoong H,
    3. Hasegawa N, et al.
    Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases. Ann Am Thorac Soc 2016; 13: 1904–1911. doi:10.1513/AnnalsATS.201604-246OC
    OpenUrlCrossRef
  7. ↵
    1. Van Ingen J,
    2. Wagner D,
    3. Gallagher J, et al.
    Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases. Eur Respir J 2017; 49: 10–13. doi:10.1183/13993003.01855-2016
    OpenUrl
  8. ↵
    1. Adjemian J,
    2. Prevots DR,
    3. Gallagher J, et al.
    Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc 2014; 11: 9–16. doi:10.1513/AnnalsATS.201304-085OC
    OpenUrlCrossRefPubMed
  9. ↵
    1. Diel R,
    2. Jacob J,
    3. Lampenius N, et al.
    Burden of non-tuberculous mycobacterial pulmonary disease in Germany. Eur Respir J 2017; 49: 1602109. doi:10.1183/13993003.02109-2016
    OpenUrlAbstract/FREE Full Text
    1. Adjemian J,
    2. Olivier KN,
    3. Seitz AE, et al.
    Spatial clusters of nontuberculous mycobacterial lung disease in the United States. Am J Respir Crit Care Med 2012; 186: 553–558. doi:10.1164/rccm.201205-0913OC
    OpenUrlCrossRefPubMed
  10. ↵
    1. Ringshausen FC,
    2. Wagner D,
    3. De RA, et al.
    Prevalence of nontuberculous mycobacterial pulmonary disease, Germany, 2009–2014. Emerging Infect Dis 2016; 22: 2014–2017. doi:10.3201/eid2206.151642
    OpenUrlCrossRef
PreviousNext
Back to top
Vol 6 Issue 1 Table of Contents
ERJ Open Research: 6 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Population-based survey of antimycobacterial drug use among patients with non-tuberculosis mycobacterial pulmonary disease
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Population-based survey of antimycobacterial drug use among patients with non-tuberculosis mycobacterial pulmonary disease
Kiyohiko Izumi, Kozo Morimoto, Kazuhiro Uchimura, Manabu Ato, Naoki Hasegawa, Satoshi Mitarai
ERJ Open Research Jan 2020, 6 (1) 00097-2019; DOI: 10.1183/23120541.00097-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Population-based survey of antimycobacterial drug use among patients with non-tuberculosis mycobacterial pulmonary disease
Kiyohiko Izumi, Kozo Morimoto, Kazuhiro Uchimura, Manabu Ato, Naoki Hasegawa, Satoshi Mitarai
ERJ Open Research Jan 2020, 6 (1) 00097-2019; DOI: 10.1183/23120541.00097-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Duration of RA and the risk of developing ILD
  • Prevalence of stress urinary incontinence in chronic cough
  • What is important for people with NTM?
Show more Original research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2021 by the European Respiratory Society